Samie Modak, Sohini Das

Stories by Samie Modak, Sohini Das

Mankind Pharma Targets Anti-Obesity Drug

Mankind Pharma Targets Anti-Obesity Drug

Rediff.com   6 Mar 2025

'Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.'

Can Tesla Make In India For Below $23,000?

Can Tesla Make In India For Below $23,000?

Rediff.com   5 Mar 2025

The Indian automotive market offers around 1 million units annual volume opportunity at a price above $23,000.

Nifty Indices Rebalance Begins

Nifty Indices Rebalance Begins

Rediff.com   3 Mar 2025

The changes will take effect on March 28, with portfolio adjustments expected before the market closes on March 27.

India Inc holds breath for Trump's new tariffs to kick in

India Inc holds breath for Trump's new tariffs to kick in

Rediff.com   27 Feb 2025

Industry insiders in India warn that any such move in the pharmaceutical sector could be counterproductive for the US as it may face increased drug shortages if tariffs are imposed on such imports.

Why Tesla Entry is No Major Threat

Why Tesla Entry is No Major Threat

Rediff.com   24 Feb 2025

Tesla needs to either sell the same models with reduced features to lower the cost for Indian market, or incur losses.

Equity MFs Gain Despite Selloff

Equity MFs Gain Despite Selloff

Rediff.com   13 Feb 2025

Among the 11 equity sub-categories, thematic funds received the highest net inflows at Rs 9,017 crore, followed by smallcap funds at Rs 5,721 crore and flexicap funds at Rs 5,698 crore.

USAID Funding To India Declines Amid Trump's Freeze

USAID Funding To India Declines Amid Trump's Freeze

Rediff.com   13 Feb 2025

'If the Bill and Melinda Gates Foundation cuts funds, there could be more impact.'

'2025 Is Year To Keep Expectations Low'

'2025 Is Year To Keep Expectations Low'

Rediff.com   12 Feb 2025

'Stay disciplined, and remain invested.' 'Volatile times are the best to invest in structural opportunities at the right price.'

Highest Selling New Drug In India Is...

Highest Selling New Drug In India Is...

Rediff.com   11 Feb 2025

Enhertu currently costs around Rs 1.6 lakh per 100-milligram injection.

'Tariffs will hurt insurance, patients and everyone'

'Tariffs will hurt insurance, patients and everyone'

Rediff.com   10 Feb 2025

After registering a net profit of Rs 25.1 crore in Q3FY25 and consolidated revenues growing by 7 per cent on a like-for-like basis, Siddharth Mittal, chief executive officer (CEO) and managing director, Biocon, told Sohini Das/Business Standard in a virtual interaction that local manufacturing in the US is a trade off between cost and qualifying to do business there.

Budget Prepares For Rise In Cancer Cases

Budget Prepares For Rise In Cancer Cases

Rediff.com   3 Feb 2025

Do we have enough trained oncologists and medical professionals in India to man these over 4,500 beds in the public sector?

Trump's Tariff War: India Waits, Watches

Trump's Tariff War: India Waits, Watches

Rediff.com   3 Feb 2025

'We have to be prepared for the larger disruption that is likely to take place.'

January Crash: Record 2,461 Stocks Flash Red

January Crash: Record 2,461 Stocks Flash Red

Rediff.com   29 Jan 2025

'The market's sharp decline recently has shaken the confidence of retail investors, leading to increased selling.'

Burmans vs Gaekwad: Who will manage to acquire Religare Enterprise?

Burmans vs Gaekwad: Who will manage to acquire Religare Enterprise?

Rediff.com   27 Jan 2025

The race to acquire diversified fintech firm Religare Enterprise Limited (REL) intensified as Dabur group promoters, the Burman family, said it was going ahead with the open offer on Monday and claimed that the counter offer made by US-based businessman Digvijay Gaekwad wasn't valid and will not stand scrutiny of market regulator Sebi. The Burman family claimed that the competing offer falls outside the 15-day window stipulated by the Sebi takeover code, following their initial offer on October 4th, 2023.

GBS Disease: 16 Patients On Ventilator

GBS Disease: 16 Patients On Ventilator

Rediff.com   27 Jan 2025

Water samples from different parts of Pune have been sent to the public health laboratory for chemical and biological analysis.

'Coming Months Could Be Eventful For Markets'

'Coming Months Could Be Eventful For Markets'

Rediff.com   15 Jan 2025

'The shifts in US involvement in global conflicts and geopolitical alliances could introduce uncertainties.'

New Tata EVs will run 500 km on single charge

New Tata EVs will run 500 km on single charge

Rediff.com   13 Jan 2025

As battery prices drop, early customers of Tata Motors, which was the first mover in the passenger EV market, could feel let down.

How is Tata Motors gearing up to face competition?

How is Tata Motors gearing up to face competition?

Rediff.com   8 Jan 2025

Why is Shailesh Chandra, managing director of Tata Motors Passenger Vehicles and Tata Passenger Electric Mobility, not worried about the competition?

Secondary Market Saw Lacklustre Funding In 2024

Secondary Market Saw Lacklustre Funding In 2024

Rediff.com   7 Jan 2025

Net flows from domestic institutional investors crossed Rs 5 trillion for the first time during a calendar year.

Tata Punch Knocks Out Maruti!

Tata Punch Knocks Out Maruti!

Rediff.com   7 Jan 2025

While Maruti held the top spot for four decades, the Ambassador was the best-selling car in post-Independence India for three decades.